Rashmi Mehta Selected Research

GSK573719

1/2020	Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
11/2018	Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD.
4/2016	Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
1/2015	Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.
1/2015	Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial.
11/2014	Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
10/2014	A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
7/2014	Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study.
7/2014	Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
5/2014	Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rashmi Mehta Research Topics

Disease

22	Chronic Obstructive Pulmonary Disease (COPD) 01/2020 - 01/2012
8	Asthma (Bronchial Asthma) 12/2022 - 11/2006
1	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 11/2023
1	Pruritus (Itching) 11/2023
1	Infections 01/2018
1	Dyspnea (Shortness of Breath) 05/2014
1	Headache (Headaches) 01/2012

Drug/Important Bio-Agent (IBA)

19	GSK573719IBA 01/2020 - 07/2012
11	vilanterolIBA 01/2020 - 12/2012
9	Muscarinic AntagonistsIBA 04/2016 - 01/2012
7	Bronchodilator Agents (Bronchodilators)IBA 12/2016 - 10/2012
4	Fluticasone (Cutivate)FDA LinkGeneric 12/2016 - 11/2006
4	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 09/2013 - 07/2012
3	Hydrocortisone (Cortisol)FDA LinkGeneric 12/2022 - 01/2008
3	fluticasone furoate FDA Link 01/2020 - 11/2018
3	Salmeterol Xinafoate (Serevent)FDA Link 12/2016 - 01/2012
2	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2022 - 12/2016
2	BromidesIBA 01/2020 - 01/2014
2	Capsules (Microcapsules)IBA 12/2016 - 08/2014
2	PowdersIBA 12/2016 - 08/2014
2	Albuterol (Salbutamol)FDA LinkGeneric 05/2014 - 11/2006
2	Tiotropium Bromide (Spiriva)FDA Link 07/2012 - 01/2012
2	apaflurane (hydrofluoroalkane)IBA 01/2008 - 11/2006
1	Bile Acids and Salts (Bile Acids)IBA 11/2023
1	TabletsIBA 01/2018
1	Rilpivirine (TMC-278)IBA 01/2018
1	dolutegravirIBA 01/2018
1	Cytochrome P-450 CYP3A InhibitorsIBA 01/2013
1	Verapamil (Calan)FDA LinkGeneric 01/2013
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2013
1	Cytochrome P-450 CYP3AIBA 01/2013
1	Cholinergic Antagonists (Anticholinergics)IBA 10/2012
1	CarbonIBA 01/2008
1	AerosolsIBA 11/2006

Therapy/Procedure

5	Nebulizers and Vaporizers (Inhaler) 01/2020 - 01/2014
4	Therapeutics 11/2018 - 01/2012